BCM
RIGL icon

Bridgeway Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bridgeway Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,520
Closed -$536K – 1306
2025
Q4 		$536K Sell
12,520
-9,950
-44% -$375K 0.01% 809
2025
Q3 		$637K Sell
22,470
-12,500
-36% -$374K 0.01% 761
2025
Q2 		$655K Sell
34,970
-12,500
-26% -$237K 0.02% 725
2025
Q1 		$854K Sell
47,470
-15,400
-24% -$312K 0.02% 667
2024
Q4 		$1.06M Sell
62,870
-1,670
-3% -$32K 0.02% 656
2024
Q3 		$1.04M Hold
64,540
– – 0.02% 673
2024
Q2 		$531K Buy
64,540
+5,000
+8% +$52.3K 0.01% 845
2024
Q1 		$881K Sell
59,540
-7,500
-11% -$101K 0.02% 772
2023
Q4 		$972K Buy
67,040
+7,620
+13% +$77.9K 0.02% 768
2023
Q3 		$642K Buy
59,420
+21,920
+58% +$264K 0.02% 820
2023
Q2 		$484K Buy
37,500
+11,500
+44% +$155K 0.01% 914
2023
Q1 		$343K Sell
26,000
-6,500
-20% -$103K 0.01% 976
2022
Q4 		$488K Hold
32,500
– – 0.01% 885
2022
Q3 		$384K Buy
+32,500
New +$440K 0.01% 963
2017
Q4 		– Sell
-15,780
Closed -$401K – 1438
2017
Q3 		$401K Hold
15,780
– – ﹤0.01% 1145
2017
Q2 		$431K Hold
15,780
– – 0.01% 1131
2017
Q1 		$522K Hold
15,780
– – 0.01% 1061
2016
Q4 		$376K Sell
15,780
-4,000
-20% -$115K ﹤0.01% 1174
2016
Q3 		$726K Buy
19,780
+780
+4% +$22.4K 0.01% 927
2016
Q2 		$424K Hold
19,000
– – 0.01% 1113
2016
Q1 		$395K Sell
19,000
-530
-3% -$13.1K 0.01% 1133
2015
Q4 		$592K Sell
19,530
-3,650
-16% -$111K 0.01% 987
2015
Q3 		$573K Buy
23,180
+3,650
+19% +$109K 0.01% 960
2015
Q2 		$627K Sell
19,530
-230
-1% -$8.79K 0.01% 963
2015
Q1 		$705K Hold
19,760
– – 0.01% 942
2014
Q4 		$449K Sell
19,760
-9,490
-32% -$192K 0.01% 1114
2014
Q3 		$567K Buy
29,250
+1,640
+6% +$46.3K 0.01% 1015
2014
Q2 		$1M Buy
27,610
+13,270
+93% +$451K 0.03% 776
2014
Q1 		$556K Buy
+14,340
New +$511K 0.02% 1024

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's RIGL Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 12,520 shares — an estimated $536K sold.

Bridgeway Capital Management first reported a position in RIGL in Q1 2014 and held it in 29 quarters. The position peaked at $1.06M in Q4 2024. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 12,520 Rigel Pharmaceuticals shares in Q1 2026, an estimated $536K.
  • Bridgeway Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2014 and held it in 29 quarters.
  • Bridgeway Capital Management's Rigel Pharmaceuticals position peaked at $1.06M in Q4 2024.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.